|Application ||IF, WB, E|
|Other Names||Fatty acid synthase, [Acyl-carrier-protein] S-acetyltransferase, [Acyl-carrier-protein] S-malonyltransferase, 3-oxoacyl-[acyl-carrier-protein] synthase, 3-oxoacyl-[acyl-carrier-protein] reductase, 3-hydroxyacyl-[acyl-carrier-protein] dehydratase, Enoyl-[acyl-carrier-protein] reductase, Oleoyl-[acyl-carrier-protein] hydrolase, FASN, FAS|
|Target/Specificity||This FASN antibody is generated from mice immunized with a KLH conjugated synthetic peptide between 942-973 amino acids from the Central region of human FASN.|
|Format||Purified monoclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is prepared by Euglobin precipitation followed by dialysis against PBS.|
|Storage||Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||FASN Antibody (Center) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Fatty acid synthetase catalyzes the formation of long- chain fatty acids from acetyl-CoA, malonyl-CoA and NADPH. This multifunctional protein has 7 catalytic activities as an acyl carrier protein.|
|Cellular Location||Cytoplasm. Melanosome. Note=Identified by mass spectrometry in melanosome fractions from stage I to stage IV|
|Tissue Location||Ubiquitous. Prominent expression in brain, lung, and liver.|
Provided below are standard protocols that you may find useful for product applications.
The enzyme encoded by this gene is a multifunctional protein. Its main function is to catalyze the synthesis of palmitate from acetyl-CoA and malonyl-CoA, in the presence of NADPH, into long-chain saturated fatty acids. In some cancer cell lines, this protein has been found to be fused with estrogen receptor-alpha (ER-alpha), in which the N-terminus of FAS is fused in-frame with the C-terminus of ER-alpha.
References for protein:
1.Bailey, S.D., et al. Diabetes Care 33(10):2250-2253(2010)
2.Nguyen, P.L., et al. J. Clin. Oncol. 28(25):3958-3964(2010)
3.Ruano, G., et al. Pharmacogenomics 11(7):959-971(2010)
4.Tischler, V., et al. Histopathology 56(6):811-815(2010)
5.Dorn, C., et al. Int J Clin Exp Pathol 3(5):505-514(2010)
References for HepG2 cell line:
1. Knowles BB, et al. (1980). Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen. Science 209: 497-499.[ PubMed: 6248960].
2. Darlington GJ, et al. (1987). Growth and hepatospecific gene expression of human hepatoma cells in a defined medium. In Vitro Cell. Dev. Biol. 23: 349-354.[PubMed: 3034851].
3. Ihrke, G; Neufeld, EB; Meads, T; Shanks, MR; Cassio, D; Laurent, M; Schroer, TA; Pagano, RE et al. (1993). "WIF-B cells: an in vitro model for studies of hepatocyte polarity". Journal of Cell Biology 123 (6): 1761–1775. [PubMed:7506266].
4. Mersch-Sundermann, V.; Knasmüller, S.; Wu, X. J.; Darroudi, F.; Kassie, F. (2004). "Use of a human-derived liver cell line for the detection of cytoprotective, antigenotoxic and cogenotoxic agents". Toxicology 198 (1–3): 329–340. [PubMed:15138059].